---
title: "Biotech IPOs are the industry’s lifeblood. Track how they’re performing."
type: "News"
locale: "zh-HK"
url: "https://longbridge.com/zh-HK/news/278886245.md"
description: "Biotech IPOs are crucial for funding drug development, with public investment supporting new drugmakers. In 2021, over 100 biotechs raised nearly $15 billion through IPOs, but activity dropped significantly in 2022, with only 11 companies pricing initial share sales. Emerging biotechs now face challenges in accessing public markets, raising questions about which will succeed and provide returns. Biopharma Dive is tracking these developments in a regularly updated database."
datetime: "2026-03-12T12:40:19.000Z"
locales:
  - [zh-CN](https://longbridge.com/zh-CN/news/278886245.md)
  - [en](https://longbridge.com/en/news/278886245.md)
  - [zh-HK](https://longbridge.com/zh-HK/news/278886245.md)
---

> 支持的語言: [简体中文](https://longbridge.com/zh-CN/news/278886245.md) | [English](https://longbridge.com/en/news/278886245.md)


# Biotech IPOs are the industry’s lifeblood. Track how they’re performing.

Initial public offerings make the biotechnology industry tick. Stock listings give young companies the funding they need to develop their drugs, and their venture backers an opportunity to earn a return.

For much of the past decade, biotechs found Wall Street receptive to their pitches. Public investment, drawn in by scientific advances and company successes, bolstered generations of new drugmakers.

IPO activity reached a peak in 2021, when more than 100 biotechs priced an initial offering and together raised nearly $15 billion. But that momentum came to a halt in 2022 as stock prices of newly public companies plummeted amid a sector-wide downturn. The pace of IPOs stalled and, last year, only 11 drugmakers priced initial share sales.

Emerging biotechs now face a tougher road to public markets. Which will make it? Which create value and which fail? What types of companies earn the best returns? Who are their investors?

Biopharma Dive is tracking these questions in the database below, which will be updated regularly. If we've missed anything, or there's any additional information you'd like to see, please reach out and let us know.

_Editor's note: Click on a company to pull up more information, and scroll to the bottom of the page to read how this information was collected and organized. If tables or values do not display below, please try clearing your browser's cache and reloading the page._

## 相關資訊與研究

- [Rusoro Mining (CVE:RML) Director Sells 60,000 Shares](https://longbridge.com/zh-HK/news/281694931.md)
- [Should Record 2025 Output and 100% U.S. Reserve Replacement Require Action From Freehold (TSX:FRU) Investors?](https://longbridge.com/zh-HK/news/281696598.md)
- [Wasion Holdings Limited (3393) Gets a Buy from China Renaissance](https://longbridge.com/zh-HK/news/281702521.md)
- [Global Prosperity Sticks to Their Buy Rating for Fufeng Group Limited (FFO1)](https://longbridge.com/zh-HK/news/281702206.md)
- [CICC Remains a Buy on Yonghe Medical Group Co., Ltd. (2279)](https://longbridge.com/zh-HK/news/281703443.md)